SCHEMBL9026418

SCHEMBL9026418

CCOc1ccc(CCCCO)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.55
MEN1 O00255 1/20 0.55
USP2 O75604 1/20 0.55
ALDH1A1 P00352 1/20 0.55
LMNA P02545 1/20 0.55
CYP3A4 P08684 1/20 0.55
MAPK1 P28482 1/20 0.55
CASP1 P29466 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
SLCO1B3 Q9NPD5 1/20 0.55
SLCO1B1 Q9Y6L6 1/20 0.55
LTA4H P09960 2/20 0.54
EPHX2 P34913 1/20 0.54
NQO1 P15559 1/20 0.54
MAPT P10636 1/20 0.50
RAB9A P51151 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CYP4F2 P78329 1/20 0.50
CYP4A11 Q02928 1/20 0.50
SIGMAR1 Q99720 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10610791 0.98 KMT2A (0.58) KMT2AMEN1USP2ALDH1A1LMNA
SCHEMBL5671708 0.94 LTA4H (0.61) KMT2AMEN1USP2ALDH1A1LMNA
SCHEMBL4248652 0.90 NQO1 (0.67) KMT2AMEN1USP2ALDH1A1LMNA
SCHEMBL10575040 0.88 NQO1 (0.64) KMT2AMEN1USP2ALDH1A1LMNA
SCHEMBL1240940 0.86 NQO1 (0.61) KMT2AMEN1USP2ALDH1A1LMNA
SCHEMBL30101910 0.85 ALDH1A1 (0.65) KMT2AMEN1USP2ALDH1A1LMNA
SCHEMBL12251519 0.84 MAPT (0.66) KMT2AMEN1USP2ALDH1A1LMNA
SCHEMBL10570997 0.84 RAB9A (0.61) KMT2AMEN1USP2ALDH1A1LMNA
SCHEMBL8521940 0.82 MAPT (0.64) KMT2AMEN1USP2ALDH1A1LMNA
SCHEMBL39534 0.82 MAPT (0.64) KMT2AMEN1USP2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398168-B2 Preparation method of a glycoside compound SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) 2025-08-26 US disclosed
US-20220380399-A1 PREPARATION METHOD OF A GLYCOSIDE COMPOUND SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) 2022-12-01 US disclosed
WO-2021139621-A1 METHOD FOR PREPARING GLYCOSIDE COMPOUND 上海和黄药业有限公司 2021-07-15 WO disclosed
EP-0411150-B1 INDOLE DERIVATIVES, PREPARATION THEREOF, AND DRUG FOR PREVENTING AND TREATING NEPHRITIS CONTAINING SAME OTSUKA PHARMA CO LTD (JP) 1996-11-27 EP disclosed
US-5459142-A Autoimmune disease, atherosclerosis, antiischemic agents and nephritis OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-10-17 US disclosed
US-5238938-A Nephrosis OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-08-24 US disclosed
EP-0411150-A1 INDOLE DERIVATIVES, PREPARATION THEREOF, AND DRUG FOR PREVENTING AND TREATING NEPHRITIS CONTAINING SAME OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-02-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398168-B2 Preparation method of a glycoside compound GALE, ST6GAL1, MGAM KMT2A 3283/4885MEN1 1680/4885USP2 2400/4885
US-20220380399-A1 PREPARATION METHOD OF A GLYCOSIDE COMPOUND GALE, ST6GAL1, MGAM KMT2A 3283/4885MEN1 1680/4885USP2 2400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.